Skip to main content

Siemens, LabCorp Sign Diagnostic Co-Development Agreement

NEW YORK (GenomeWeb News) - Siemens Healthcare and Laboratory Corporation of America have agreed to "discuss future possibilities" to co-develop clinical diagnostic tests, the companies said today.
 
The non-exclusive agreement encompasses the areas of metabolic syndrome, oncology, diabetes, and companion diagnostics that are "designed to identify the suitability between patients and a particular drug therapy," the partners said.
 
"This agreement establishes a framework that gives both companies the opportunity to offer new diagnostic tests to laboratories, physicians and their patients more quickly and effectively than either could do alone," said Dave Hickey, senior vice president of strategic planning and business development at Siemens Healthcare Diagnostics, in a statement.
 
Myla Lai-Goldman, executive vice president, chief scientific officer, and medical director for LabCorp, said that the firm is particularly interested in the impact of the collaboration on the reference lab’s companion diagnostics efforts.
 
"Alliances, such as this between developers and providers of new tests, are critical in translating emerging biomarkers from research into clinical practice," she said.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.